Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.59 |
| ▸ | MYC | P01106 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17921444 | 0.87 | MYC (0.48) | DHODHMYCCTSBKLKB1ELANE | |
| SCHEMBL17910007 | 0.84 | DHODH (0.50) | DHODH | |
| SCHEMBL15973841 | 0.79 | MCL1 (0.51) | DHODH | |
| SCHEMBL15986658 | 0.79 | DHODH (0.58) | DHODHMYCCTSBKLKB1ELANE | |
| SCHEMBL25939461 | 0.79 | DHODH (0.58) | DHODHMYCCTSBKLKB1ELANE | |
| SCHEMBL23645717 | 0.77 | DHODH (0.37) | DHODH | |
| SCHEMBL17921456 | 0.77 | DHODH (0.52) | DHODHMYCCTSBKLKB1ELANE | |
| SCHEMBL25939456 | 0.77 | DHODH (0.52) | DHODHMYCCTSBKLKB1ELANE | |
| SCHEMBL17909998 | 0.75 | MAPT (0.41) | DHODHCTSBKLKB1TDP1ALDH1A1 | |
| SCHEMBL23645576 | 0.74 | DHODH (0.57) | DHODHMYCCTSBKLKB1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3417850-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-12-26 | — | — | EP | claimed |
| EP-3019482-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-05-18 | — | — | EP | claimed |
| WO-2014128669-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-28 | — | — | WO | claimed |
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3915557-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915557-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2021-12-01 | — | — | EP | disclosed |
| US-11147801-B2 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-10-19 | — | — | US | disclosed |
| EP-3615027-B1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-07-14 | — | — | EP | disclosed |
| US-20210113531-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES | SERVIER PHARMACEUTICALS LLC | 2021-04-22 | — | — | US | disclosed |
| WO-2019164794-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20180021311-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20170224663-A1 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-10 | — | — | US | disclosed |
| US-20170224663-A1 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-10 | — | — | US | disclosed |
| US-9630932-B2 | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2017-04-25 | — | — | US | disclosed |
| US-9630932-B2 | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2017-04-25 | — | — | US | disclosed |
| US-20160200693-A1 | Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2016-07-14 | — | — | US | disclosed |
| US-20160200693-A1 | Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2016-07-14 | — | — | US | disclosed |
| EP-3019482-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-05-18 | — | — | EP | disclosed |
| WO-2014128669-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021311-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | DHODH, DHFR, DPYD | DHODH 1/4885MYC 864/4885CTSB 1449/4885 |
| US-11717512-B2 | Methods of use for trisubstituted benzotriazole derivatives | BRDT, BRPF3, BRD4 | DHODH 441/4885MYC 261/4885CTSB 1670/4885 |
| US-20160200693-A1 | Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | DHODH, HAAO, TALDO1 | DHODH 1/4885MYC 4400/4885CTSB 2949/4885 |
| US-11147801-B2 | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | DHODH, DHFR, DDO | DHODH 1/4885MYC 1067/4885CTSB 1343/4885 |
| US-20210113531-A1 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES | BRDT, BRPF3, BRD4 | DHODH 441/4885MYC 261/4885CTSB 1670/4885 |
| US-20170224663-A1 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors | DHODH, DHFR, DDO | DHODH 1/4885MYC 1067/4885CTSB 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.